TherapeuticsMD Inc (NASDAQ:TXMD) has earned an average broker rating score of 1.33 (Strong Buy) from the six brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and five have given a strong buy recommendation to the company. TherapeuticsMD’s rating score has declined by 33% in the last three months as a result of a number of analysts’ upgrades and downgrades.
Brokerages have set a 1 year consensus price objective of $18.40 for the company and are expecting that the company will post ($0.10) earnings per share for the current quarter, according to Zacks. Zacks has also assigned TherapeuticsMD an industry rank of 161 out of 265 based on the ratings given to related companies.
A number of equities analysts have recently issued reports on TXMD shares. Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Friday, May 12th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $33.00 price objective on shares of TherapeuticsMD in a report on Wednesday, May 10th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $15.00 price objective on shares of TherapeuticsMD in a report on Monday, April 17th. Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 price objective on shares of TherapeuticsMD in a report on Monday, April 24th. Finally, CIBC reiterated a “market perform” rating and issued a $12.00 price objective on shares of TherapeuticsMD in a report on Tuesday, May 9th.
TherapeuticsMD (NASDAQ:TXMD) traded up 19.42% during mid-day trading on Monday, hitting $5.35. The stock had a trading volume of 8,168,165 shares. The stock’s market capitalization is $1.09 billion. TherapeuticsMD has a 52 week low of $3.50 and a 52 week high of $8.88. The company’s 50 day moving average is $4.37 and its 200-day moving average is $5.66.
Institutional investors have recently bought and sold shares of the company. Raymond James Financial Services Advisors Inc. boosted its position in TherapeuticsMD by 56.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company’s stock worth $207,000 after buying an additional 10,330 shares during the last quarter. Greenwood Capital Associates LLC boosted its position in TherapeuticsMD by 17.5% in the first quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock worth $146,000 after buying an additional 3,022 shares during the last quarter. JPMorgan Chase & Co. boosted its position in TherapeuticsMD by 2.5% in the first quarter. JPMorgan Chase & Co. now owns 13,725,853 shares of the company’s stock worth $98,827,000 after buying an additional 329,245 shares during the last quarter. Stifel Financial Corp boosted its position in TherapeuticsMD by 125.4% in the first quarter. Stifel Financial Corp now owns 429,362 shares of the company’s stock worth $3,091,000 after buying an additional 238,885 shares during the last quarter. Finally, American International Group Inc. boosted its position in TherapeuticsMD by 7.1% in the first quarter. American International Group Inc. now owns 92,415 shares of the company’s stock worth $665,000 after buying an additional 6,103 shares during the last quarter.
TRADEMARK VIOLATION WARNING: This news story was originally posted by WKRB News and is the property of of WKRB News. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.wkrb13.com/markets/2230809/therapeuticsmd-inc-txmd-given-18-40-consensus-target-price-by-brokerages.html.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230809/therapeuticsmd-inc-txmd-given-18-40-consensus-target-price-by-brokerages.html
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.